|
Senior Living |
|
Arthritis / Rheumatology News From Medical News Today
|
Latest Arthritis / Rheumatology News From Medical News Today.
|
-
Pipex Pharmaceuticals Acquires Late-Stage Oral Phase II Candidate For Rheumatoid Arthritis
Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of central nervous system and autoimmune diseases, today announced that it has acquired an oral, once-daily candidate for the treatment of rheumatoid arthritis (RA) which has completed a 160 patient, multi-center, double-blind, randomized, placebo-controlled Phase II clinical trial for the treatment of rheumatoid arthritis (RA).
-
Major Survey Shows Deficiency In Geriatric Care
In England, a large portion of the population is not receiving adequate basic care from the National Health Service and private healthcare systems, especially older and weaker people, according to a study released on August 15, 2008 in BMJ. As the populations in developed countries such as England become collectively older, health coverage issues for seniors and older adults are becoming increasingly important.
-
Scientists To Develop Rheumatoid Arthritis Vaccine
Scientists in the UK are hoping to develop a new vaccine using patients' own blood cells to suppress the effects of rheumatoid arthritis; if successful the work will signal a major breakthrough in the treatment of the auto-immune disease. Newcastle University's Musculoskeletal Research Group is to carry out the research, which is being funded by a 216,000 pound grant from the medical research charity the Arthritis Research Campaign.
-
Inflammation And Immunologic Symposium Explores New Research In Chronic Diseases
For the first time in the United States, more than 200 scientists from around the world will gather to explore research challenging conventional theories about immunology, inflammation and their link to acute and chronic diseases. The Damage Associated Molecular Pattern Molecules (DAMPs) and Alarmins Symposium will be held at the Hillman Cancer Center, 5115 Centre Ave., Pittsburgh, Aug. 30 through Sept. 2.
-
Mesoblast Limited Stem Cells Regrow Knee Cartilage In Severe Post-Menopausal Osteoarthritis
Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), announced successful preclinical trial results which showed that its proprietary adult stem cells regenerated and regrew damaged knee cartilage in post-menopausal osteoarthritis.
-
Key Clinical Studies Of Regeneron's ARCALYST (rilonacept) For Treatment Of CAPS Published
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced the publication of the results of three studies which supported the U.S. Food and Drug Administration (FDA) regulatory submission for ARCALYST® (rilonacept) Injection for Subcutaneous Use for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS). Two studies were published in the August 2008 issue of Arthritis and Rheumatism, the flagship publication of the American College of Rheumatology.
-
Low Vitamin D Levels Associated With Chronic Pain In Women
Low vitamin D levels may contribute to chronic pain among women, suggests research published ahead of print in the Annals of the Rheumatic Diseases. The findings are based on the blood analyses and pain scores of almost 7000 45 year old men and women from across England, Scotland and Wales, all of whom were born during one week in March 1958. Smokers, non-drinkers, the overweight and the underweight all reported higher rates of chronic pain.
-
B Cells Can Act Alone In Autoimmune Disease, Yale Researchers Report
B cells, the source of damaging autoantibodies, have long been thought to depend upon T cells for their activation and were not considered important in the initiation of autoimmune diseases like lupus or rheumatoid arthritis. In the Aug. 7 online issue of the journal of Immunity, Yale University researchers turn this paradigm on its head by showing that in systemic autoimmune diseases B cells can be activated the absence of T cells.
-
SCOLR Pharma, Inc. Submits Abbreviated New Drug Application For A 12-hour CDT-based Pseudoephedrine Formulation
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 89 percent of surveyed rheumatologists anticipate prescribing Roche/Chugai's Actemra, following the expected launch of the drug for rheumatoid arthritis in 2009.
-
Orthokine Treatment Is Effective For Knee Arthritis, Even After Two Years - Long-Study Confirms Effectiveness Of Autologous Therapy
The results of a two-year representative study of osteoarthritis of the knee, published in the internationally renowned journal "Osteoarthritis and Cartilage", confirm the safety and effectiveness of Orthokine therapy, in which anti inflammatory proteins obtained from the patient's own blood are injected into the arthritic joint.
|
|
News & Information 
